Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Jane Reusch to Hypoglycemic Agents

This is a "connection" page, showing publications Jane Reusch has written about Hypoglycemic Agents.

 
Connection Strength
  
 
 
2.849
  
  1. Reusch JE. Building a Better Insulin - Whom Will It Help? N Engl J Med. 2023 Jul 27; 389(4):372-373.
    View in: PubMed
    Score: 0.538
  2. Abushamat LA, Reusch JEB. Evolving Concepts of Type 2 Diabetes Management. Med Clin North Am. 2021 Nov; 105(6):955-966.
    View in: PubMed
    Score: 0.473
  3. Reusch JE, Manson JE. Management of Type 2 Diabetes in 2017: Getting to Goal. JAMA. 2017 03 14; 317(10):1015-1016.
    View in: PubMed
    Score: 0.346
  4. Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, Reinhardt RR, Bode BW. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014 Dec; 16(12):1257-64.
    View in: PubMed
    Score: 0.292
  5. Abel ED, Ingelfinger JR, Linhales Barker S, Peek M, Reusch JEB, Rosen CJ. Type 2 Diabetes - Controlling the Epidemic, Episode 4: Understanding Old and New Therapies for Diabetes. N Engl J Med. 2023 Oct 19; 389(16):e31.
    View in: PubMed
    Score: 0.137
  6. Reusch JE, Gadsby R. Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes. Diabetes Technol Ther. 2003; 5(4):685-93.
    View in: PubMed
    Score: 0.129
  7. Raghavan S, Warsavage T, Liu WG, Raffle K, Josey K, Saxon DR, Phillips LS, Caplan L, Reusch JEB. Trends in Timing of and Glycemia at Initiation of Second-line Type 2 Diabetes Treatment in U.S. Adults. Diabetes Care. 2022 06 02; 45(6):1335-1345.
    View in: PubMed
    Score: 0.124
  8. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, George JT, Gerstein HC, Hobbs T, Holman RR, Lawson FC, Leiter LA, Pfeffer MA, Reusch J, Riesmeyer JS, Roe MT, Rosenberg Y, Temple R, Wiviott S, McMurray J, Granger C. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. Circulation. 2020 03 10; 141(10):843-862.
    View in: PubMed
    Score: 0.106
  9. Bjornstad P, Sch?fer M, Truong U, Cree-Green M, Pyle L, Baumgartner A, Garcia Reyes Y, Maniatis A, Nayak S, Wadwa RP, Browne LP, Reusch JEB, Nadeau KJ. Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus. Circulation. 2018 12 18; 138(25):2895-2907.
    View in: PubMed
    Score: 0.098
  10. Bjornstad P, Cree-Green M, Baumgartner A, Coe G, Reyes YG, Sch?fer M, Pyle L, Regensteiner JG, Reusch JE, Nadeau KJ. Achieving ADA/ISPAD clinical guideline goals is associated with higher insulin sensitivity and cardiopulmonary fitness in adolescents with type 1 diabetes: Results from RESistance to InSulin in Type 1 ANd Type 2 diabetes (RESISTANT) and Effects of MEtformin on CardiovasculaR Function in AdoLescents with Type 1 Diabetes (EMERALD) Studies. Pediatr Diabetes. 2018 05; 19(3):436-442.
    View in: PubMed
    Score: 0.090
  11. Scalzo RL, Moreau KL, Ozemek C, Herlache L, McMillin S, Gilligan S, Huebschmann AG, Bauer TA, Dorosz J, Reusch JE, Regensteiner JG. Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes. J Diabetes Complications. 2017 Feb; 31(2):449-455.
    View in: PubMed
    Score: 0.084
  12. Reusch JE. New directions in treating insulin resistance. Hosp Pract (1995). 1995 Sep 15; 30(9):9-10.
    View in: PubMed
    Score: 0.078
  13. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2009 Oct; 25(10):2361-71.
    View in: PubMed
    Score: 0.052
  14. Rosenstock J, Reusch J, Bush M, Yang F, Stewart M. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009 Oct; 32(10):1880-6.
    View in: PubMed
    Score: 0.051
  15. Regensteiner JG, Bauer TA, Reusch JE. Rosiglitazone improves exercise capacity in individuals with type 2 diabetes. Diabetes Care. 2005 Dec; 28(12):2877-83.
    View in: PubMed
    Score: 0.040
  16. Reusch JE. Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndrome. Am J Cardiol. 2002 Sep 05; 90(5A):19G-26G.
    View in: PubMed
    Score: 0.032
  17. Love KM, Barrett EJ, Malin SK, Reusch JEB, Regensteiner JG, Liu Z. Diabetes pathogenesis and management: the endothelium comes of age. J Mol Cell Biol. 2021 10 21; 13(7):500-512.
    View in: PubMed
    Score: 0.030
  18. Redondo MJ, Libman I, Maahs DM, Lyons SK, Saraco M, Reusch J, Rodriguez H, DiMeglio LA. The Evolution of Hemoglobin A1c Targets for Youth With Type 1 Diabetes: Rationale and Supporting Evidence. Diabetes Care. 2021 02; 44(2):301-312.
    View in: PubMed
    Score: 0.028
  19. Love KM, Liu J, Regensteiner JG, Reusch JEB, Liu Z. GLP-1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. J Diabetes. 2020 Jul; 12(7):488-498.
    View in: PubMed
    Score: 0.027
  20. Scalzo RL, Rafferty D, Schauer I, Huebschmann AG, Cree-Green M, Reusch JEB, Regensteiner JG. Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes. J Diabetes Complications. 2019 08; 33(8):561-566.
    View in: PubMed
    Score: 0.025
  21. Reusch JE. Focus on insulin resistance in type 2 diabetes: therapeutic implications. Diabetes Educ. 1998 Mar-Apr; 24(2):188-93.
    View in: PubMed
    Score: 0.023
  22. Home PD, Ahr?n B, Reusch JEB, Rendell M, Weissman PN, Cirkel DT, Miller D, Ambery P, Carr MC, Nauck MA. Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. Diabetes Res Clin Pract. 2017 Sep; 131:49-60.
    View in: PubMed
    Score: 0.022
  23. Boehncke S, Poettgen K, Maser-Gluth C, Reusch J, Boehncke WH, Badenhoop K. [Endurance capabilities of triathlon competitors with type 1 diabetes mellitus]. Dtsch Med Wochenschr. 2009 Apr; 134(14):677-82.
    View in: PubMed
    Score: 0.012
  24. Nadeau KJ, Ehlers LB, Aguirre LE, Reusch JE, Draznin B. Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone. Diabetes Obes Metab. 2007 Sep; 9(5):714-23.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)